As the Director of Drug Substance and Early Development, you will lead early development activities for our clinical-stage biologics pipeline, including monoclonal antibodies and fusion proteins. This role will be instrumental in advancing our drug substance development strategy, including formulation, cell line development, bioreactor scale-up and tech transfer, ensuring robust, scalable, and compliant processes to support clinical and future commercial manufacturing.